Bioneer (064550) Fundamentals 2026 — Revenue Analysis | SniperIQ
Bioneer (064550) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩155.4B, trading at ₩6020.00 on the KOE. This SniperIQ fundamentals page covers Bioneer's valuation, profitability (net margin -1.7%), revenue (₩330.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bioneer's market cap?
Bioneer (064550) has a market capitalization of approximately ₩155.4B, trading at ₩6020.00 on the KOE. Market cap moves with the live share price.
What is Bioneer's P/E ratio?
Bioneer's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Bioneer?
Bioneer runs a net profit margin of -1.7%, a gross margin of 77.4%, and an operating margin of 1.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bioneer generate?
Bioneer reported revenue of ₩330.1B for fiscal year 2025, with net income of -₩2.8B and earnings per share (EPS) of -108.99. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Bioneer pay a dividend?
Bioneer does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Bioneer financially healthy?
Bioneer carries a debt-to-equity ratio of 0.52x and a current ratio of 2.04x, with a market beta of 0.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bioneer a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bioneer (064550) the key facts are: market cap ₩155.4B, revenue ₩330.1B, 52-week range 5870-16620. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Bioneer's full fundamentals live
Get Bioneer's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.